Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in…
Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the…
Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the…
DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…
The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatments…
DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…
Clarivate Epidemiology’s coverage of hemophilia B comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia B for each…
Clarivate Epidemiology’s coverage of hemophilia A comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of hemophilia A for each…